Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 31, Number 11—November 2025

Synopsis

Trichosporon austroamericanum Infections among Hospitalized Patients, France, 2022–2024

Emilie Burel, Catherine Sartor, Valérie Moal, Vincent Bossi, Jacques Sevestre, Justine Solignac, Rémi Charrel, Marie Desnos-Ollivier, Stéphane Ranque, and Estelle MenuComments to Author 
Author affiliation: Aix-Marseille Université, Marseille, France (E. Burel); Institut Méditerranée-Infection, Marseille (E. Burel, V. Bossi); Assistance Publique Hôpitaux de Marseille, Hôpital Conception, Equipe Opérationnelle d'Hygiène Hospitalière, Marseille (C. Sartor, R. Charrel); Aix Marseille Université, Institut de Recherche et Développement, Microbes Evolution Phylogeny and Infections, Marseille (V. Moal); Assistance Publique Hôpitaux de Marseille, Hôpital Conception, Centre de Néphrologie et Transplantation Rénale, Marseille (V. Moal, J. Solignac); UMR D257 RITMES, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Service de Santé des armées, Marseille (J. Sevestre, S. Ranque, E. Menu); Unité des Virus Émergents, Aix-Marseille Université, Università di Corsica, IRD 190, Inserm 1207, IRBA, Marseille (R. Charrel); Institut Pasteur, Université Paris Cité, National Reference Center for Invasive Mycoses & Antifungals, Mycology Translational Research Group, Paris, France (M. Desnos-Ollivier)

Main Article

Table 2

Antifungal susceptibility testing of isolates from investigation of Trichosporon austroamericanum infections among hospitalized patients, France, 2022–2024*

Strain no. MIC per antifungal agent, µg/mL
AMB 5-FC FCZ ITC VRC POS CAS MCF AND
L0221 1 64 0.5 0.12 0.03 0.12 8 8 8
L0385 0.25 32 0.5 0.06 0.015 0.06 >8 >8 >8
L0399 0.25 16 1 0.06 0.015 0.12 >8 >8 >8
L0419 0.12 >64 1 0.06 0.015 0.06 >8 >8 >8
L0445 2 >64 1 0.12 0.03 0.25 >8 >8 >8
L0458 0.5 32 1 0.12 0.03 0.12 8 8 8

*AMB, amphotericin B; ANI, anidulafungin; CAS, caspofungin; FCZ, fluconazole; ITC, itraconazole; MIF, micafungin; VRC, voriconazole; POS, posaconazole; 5-FC, 5-Fluorocytosine.

Main Article

Page created: September 18, 2025
Page updated: December 10, 2025
Page reviewed: December 10, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external